Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Net Income: 2019-2024

Historic Net Income for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$261.9 million.

  • Kymera Therapeutics' Net Income fell 28.31% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 65.94%. This contributed to the annual value of -$261.9 million for FY2024, which is 58.02% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Net Income of -$261.9 million as of FY2024, which was down 58.02% from -$165.7 million recorded in FY2023.
  • Kymera Therapeutics' Net Income's 5-year high stood at -$46.4 million during FY2020, with a 5-year trough of -$261.9 million in FY2024.
  • Over the past 3 years, Kymera Therapeutics' median Net Income value was -$165.7 million (recorded in 2023), while the average stood at -$196.3 million.
  • Data for Kymera Therapeutics' Net Income shows a maximum YoY tumbled of 116.95% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Net Income stood at -$46.4 million in 2020, then plummeted by 116.95% to -$100.7 million in 2021, then slumped by 60.30% to -$161.4 million in 2022, then declined by 2.66% to -$165.7 million in 2023, then slumped by 58.02% to -$261.9 million in 2024.